Skin neoplasm excision Trials in Disease

Study of INCB099280 for Patients with Advanced Solid Tumors Who Have Not Received Immunotherapy

This study is examining a new medication called INCB099280 for people with advanced solid tumors that have either spread to other parts of the body or returned after previous treatment. The medication is taken as a tablet by mouth twice daily, and the study is testing three different doses: 400 mg, 600 mg, and 800 mg.

Who can join this trial:

• Adults aged 18 years or older
• People who have not previously received immunotherapy for their cancer
• Those with measurable disease according to specific medical guidelines
• People who have a life expectancy of more than 3 months
• Those with a performance score showing they can manage daily activities reasonably well
• Participants willing to use appropriate birth control during the study

Who cannot join this trial:

• People who have already received immunotherapy treatment
• Those with certain medical conditions not suitable for the study
• People outside the specified age range
• Members of vulnerable populations not included in the study design

What the study aims to learn:

The main goal is to understand how safe and tolerable INCB099280 is for patients with advanced solid tumors. Researchers will monitor participants for side effects and measure how well the treatment works by looking at whether tumors shrink or stop growing. The study will also examine how long any positive effects last and how the treatment affects overall health and survival.

The investigational drug:

INCB099280 is an immune checkpoint inhibitor that works by helping the body's immune system recognize and fight cancer cells more effectively. It is administered orally as a film-coated tablet taken twice daily. The study will assess its safety, tolerability, and potential effectiveness in managing advanced solid tumors, particularly in patients who have not previously been treated with immunotherapy.

Study on the Safety and Effects of ATL001 and Nivolumab for Adults with Metastatic or Recurrent Melanoma

This trial focuses on a type of skin cancer called melanoma that has spread to other parts of the body or has returned after treatment. The study is testing a personalized cell therapy called ATL001, which uses the patient's own immune cells that have been modified to better recognize and attack cancer cells. Some participants will also receive nivolumab, a medication that helps the immune system fight cancer by blocking a protein that prevents immune cells from attacking cancer.

Who can join this trial:

• Adults aged 18 years or older
• People with metastatic or recurrent melanoma
• Those with a life expectancy of at least 6 months
• People who have previously received a PD-1/PD-L1 inhibitor treatment
• Participants with a performance status showing they are fully active or have some symptoms but can manage daily activities
• Those with adequate organ function based on blood test results
• Women of childbearing potential and men must agree to use effective birth control methods

Who cannot join this trial:

• People with other types of cancer besides metastatic or recurrent melanoma
• Those who cannot provide informed consent or understand the study requirements
• Pregnant or breastfeeding women
• People with certain medical conditions that might interfere with the study or worsen with treatment
• Those currently participating in another clinical trial
• People who have recently had major surgery or are still recovering
• Those with a history of severe allergic reactions to similar treatments
• People with active infections requiring treatment

What the study aims to learn:

The study is designed to evaluate the safety and effectiveness of using ATL001 alone and in combination with nivolumab. Researchers will monitor participants through regular check-ups and tests to observe any side effects and see how the cancer responds to treatment. The study will examine changes in tumor size, overall survival rates, and quality of life for participants.

The investigational drugs:

ATL001 is a personalized immunotherapy that uses specially modified T cells designed to recognize and attack cancer cells in patients with melanoma. These cells are reactive to neoantigens, which are unique markers found on cancer cells. The treatment is given as an infusion directly into the bloodstream after tissue is collected from the patient's tumor to create the personalized therapy.

Nivolumab is a checkpoint inhibitor that works by blocking a protein called PD-1 on T cells, which enhances the immune response against cancer cells. It is also administered as an intravenous infusion and is used in combination with ATL001 in some cases to help the immune system more effectively recognize and attack melanoma cells.

Summary

Both trials represent important research in the field of cancer immunotherapy. The first trial is taking place across three countries in Europe: Greece, Hungary, and Romania, focusing on patients with various types of advanced solid tumors who have not previously received immunotherapy. The second trial is being conducted in Spain and specifically targets patients with metastatic or recurrent melanoma.

A common theme across both studies is the use of immunotherapy approaches that help the body's immune system fight cancer more effectively. The first study uses INCB099280, an immune checkpoint inhibitor taken orally, while the second study combines a personalized cell therapy with an established checkpoint inhibitor medication. Both trials carefully monitor participants for safety and effectiveness, with regular assessments to track how the cancer responds to treatment.

These studies offer opportunities for patients who meet specific criteria to access potentially promising new treatments while contributing to medical research that may benefit future patients with similar conditions.